Antengene raises $120mm in Series B round

Antengene Corp. (cancer and infectious disease drug development) raised $120mm through its Series B round. Boyu Capital and FountainVest led and were joined by Celgene, Wuxi Corporate Venture Fund, and Taikang, along with returning backers Qiming Venture Partners and TF Capital. Proceeds will support continued development of lead projects ATG008, a second generation TORC1/2 inhibitor in-licensed from Celgene and in Phase II for HBV+ hepatocellular carcinoma, and ATG010 (selinexor), in Phase III for blood and solid tumors including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, and glioblastoma. The company previously raised $21mm in its 2017 Series A round.